Adbry Dosage

Generic name: TRALOKINUMAB 150mg in 1mL
Dosage form: injection, solution
Drug class: Interleukin inhibitors

Medically reviewed by Drugs.com. Last updated on Dec 14, 2023.

Vaccination Prior to Treatment

Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with ADBRY [see Warnings and Precautions (5.4)].

Important Administration Instructions

ADBRY is administered by subcutaneous injection.
ADBRY is intended for use under the guidance of a healthcare provider. Provide proper training to patients and/or caregivers on the preparation and administration according to the "Instructions for Use" [see Instructions for Use]. A patient may self-inject after training in subcutaneous injection technique. In pediatric patients 12 years of age and older, it is recommended that ADBRY be given by or under supervision of an adult.
For the initial loading dose of 600 mg, administer each of the four ADBRY 150 mg injections at different injection sites within the same body area.
- For the subsequent 300 mg doses, administer the two ADBRY 150 mg injections at different injection sites within the same body area, rotating the body area with each subsequent set of injections.
For the initial loading dose of 300 mg, administer the two ADBRY 150 mg injections at different injection sites within the same body area.
- For the subsequent 150 mg doses, administer one ADBRY 150 mg injection, rotating the body area with each subsequent injection.
Administer subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel. The upper arm can also be used if a caregiver administers the injection.
DO NOT inject ADBRY into skin that is tender, damaged, bruised, or scarred.

Recommended Dosage

The recommended dosage of ADBRY for adults and pediatric patients 12 to 17 years old is:

	Initial Loading Dose	Subsequent Dosage
Adults 18 years and older	600 mg (four 150 mg injections)	300 mg (two 150 mg injections) every other week
Pediatric Patients 12 to 17 years old	300 mg (two 150 mg injections)	150 mg (one 150 mg injection) every other week

After 16 weeks of treatment, for adult patients with body weight below 100 kg who achieve clear or almost clear skin, a dosage of 300 mg every 4 weeks may be considered.

Concomitant Topical Therapies

ADBRY can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas.

Missed Doses

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

Preparation for Use

Before injection, remove ADBRY prefilled syringes from the refrigerator and allow to reach room temperature (30 minutes for the 150 mg/mL prefilled syringes) without removing the needle cap.
After removal from the refrigerator, prefilled syringes may be kept at room temperature up to 30°C (86°F) and must be used within 14 days or discarded.
Inspect visually for particulate matter and discoloration prior to administration. ADBRY injection is a clear to opalescent, colorless to pale yellow solution. Do not use if the liquid contains visible particulate matter, is discolored or cloudy (other than clear to opalescent, colorless to pale yellow).
ADBRY does not contain preservatives; therefore, discard any unused product.